Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Prostatic Neoplasms 23Lung Neoplasms 17Breast Neoplasms 16Squamous Cell Carcinoma of Head and Neck 13Neoplasms 9Stomach Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 5Endometrial Neoplasms 5Carcinoma, Squamous Cell 5Prostatic Neoplasms, Castration-Resistant 4Oropharyngeal Neoplasms 4Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Ovarian Neoplasms 3Nasopharyngeal Carcinoma 3HER2-positive Breast Cancer 3Esophageal Squamous Cell Carcinoma 3Carcinoma 3Anatomic Stage I Breast Cancer AJCC v8 3Adenocarcinoma 3Vaccinia 2Solid Tumors 2Sarcoma 2

Interventions

Specimen Handling 4Magnetic Resonance Spectroscopy 4Doxorubicin 4pembrolizumab 3Radiotherapy 3Radiation 3Biopsy 3pazopanib 2palbociclib 2abemaciclib 2Immunoglobulin G 2Ifosfamide 2toripalimab 1talimogene laherparepvec 1silmitasertib 1selinexor 1ribociclib 1peposertib 1mirdametinib 1liposomal doxorubicin 1eribulin 1durvalumab 1cemiplimab 1X-Rays 1Vincristine 1Temozolomide 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Proton Therapy 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma × Docetaxel × 90 days × Clear all
NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡